ScholarIQanswers from OpenAlex & ORCID
Federico Cappuzzo
ResearcherPublications, citations & collaboration network
Federico Cappuzzo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Federico Cappuzzo have?
ScholarIQindexed works
Federico Cappuzzo has 819 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Federico Cappuzzo have?
ScholarIQcitation count
Federico Cappuzzo has 49,371 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Federico Cappuzzo?
ScholarIQh-index
Federico Cappuzzo has an h-index of 89 in OpenAlex.
What is the i10-index of Federico Cappuzzo?
ScholarIQi10-index
Federico Cappuzzo has an i10-index of 272 in OpenAlex.
What is the ORCID of Federico Cappuzzo?
ScholarIQorcid
The ORCID for Federico Cappuzzo is on the source record.
What is the OpenAlex record for Federico Cappuzzo?
ScholarIQopenalex
The OpenAlex for Federico Cappuzzo is on the source record.
What are the most-cited papers on Federico Cappuzzo?
ScholarIQmost cited works
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock, Bart Claes, David Bernasconi, Jef De Schutter, Bart Biesmans, George Fountzilas, Konstantine T. Kalogeras, Vassiliki Kotoula, Demetris Papamichael, Pierre Laurent‐Puig, Frédérique Penault–Llorca, Philippe Rougier, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Federico Cappuzzo, Milo Frattini, Francesca Molinari, Piercarlo Saletti, Sara De Dosso, Miriam Martini, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi, Josep Tabernero, Teresa Macarulla, Frédéric FIORE, Alice Gangloff, Fortunato Ciardiello, Per Pfeiffer, Camilla Qvortrup, Tine Plato Hansen, Eric Van Cutsem, Hubert Piessevaux, Diether Lambrechts, Mauro Delorenzi, Sabine Tejpar
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam